- Home
- RPRX
RPRX
Royalty Pharma plc
as 02-24-2025 4:00pm EST
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
| Founded: | 1996 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 14.0B | IPO Year: | 2020 |
| Target Price: | $41.60 | AVG Volume (30 days): | 4.6M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | Dividend Payout Frequency: | Quarterly | |
| EPS: | 1.91 | EPS Growth: | -24.54 |
| 52 Week Low/High: | $24.05 - $34.16 | Next Earning Date: | 02-11-2025 |
| Revenue: | $2,263,576,000 | Revenue Growth: | -3.86% |
| Revenue Growth (this year): | 29.18% | Revenue Growth (next year): | 9.99% |
Latest Royalty Pharma plc News
RPRX Breaking Stock News: Dive into RPRX Ticker-Specific Updates for Smart Investing
Insider Monkey
2 days ago
Why Royalty Pharma Plc (RPRX) is the Best Performing Pharma Stock So Far in 2025
Morningstar Research
11 days ago
Analyst Report: Royalty Pharma plc
Morningstar Research
13 days ago
Analyst Report: Royalty Pharma plc
GlobeNewswire
13 days ago
Royalty Pharma Announces R&D Funding Collaboration With Biogen
GuruFocus.com
13 days ago
Royalty Pharma PLC (RPRX) Q4 2024 Earnings Call Highlights: Strong Financial Performance and ...
StockStory
14 days ago
Royalty Pharma (NASDAQ:RPRX) Misses Q4 Revenue Estimates
GlobeNewswire
14 days ago
Royalty Pharma Reports Q4 and Full Year 2024 Results
StockStory
15 days ago
Royalty Pharma Earnings: What To Look For From RPRX
Compare RPRX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "RPRX Royalty Pharma plc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.